Table 3. Seroprevalence of IgG antibodies to Chikungunya (CHIKV), O’nyong nyong (ONNV), Zika (ZIKV), Dengue (DENV), Usutu (USUV) and West Nile (WNV) viruses in monkeys stratified by collection site shown in Fig 1.
| CHIKV_E2 | ONNV_E2# | ZIKV_NS1 | DENV1_NS1 | DENV2_NS1 | DENV3_NS1 | DENV4_NS1 | > 1 DENV NS1 | USUV_NS1* | WNV_NS1* | WNV_DIII* | Totala (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cameroon (n = 1470) | ||||||||||||
| Pets (n = 175) | -b | 2 (1.1%) c | - | 2 (1.1) | - | 1 (0.5) | 1 (0.5) | 2 (1.1) | - | 1 (0.5) | 5 (2.8) | 8/175 (4.5) |
| BP (n = 19) | 1 (5.2) | 1 (5.2%) | 1 (5.2) | 1 (5.2) | 1 (5.2) | - | 1 (5.2) | 1 (5.2) | 1 (5.2) | - | - | 3/19 (15.7) |
| ND (n = 65) | - | 1 (1.5%) | 1 (1.5) | 1 (1.5) | 1 (1.5) | 1 (1.5) | 2 (3.0) | 1 (5.2) | 1 (1.5) | 1 (1.5) | 1 (1.5) | 5/65 (7.69) |
| YD (n = 96) | - | - | 2 (2.0) | 1 (1.0) | 1 (1.0) | - | 3 (3.1) | 2 (2.0) | 1 (1.0) | 1 (1.0) | - | 5/96 (5.20) |
| BQ (n = 51) | 1 (1.9) | 4 (7.8%) | 2 (3.9) | 3 (5.9) | 5 (9.8) | 3 (5.9) | 5 (9.8) | 4 (4.2) | 2 (3.9) | 4 (7.8) | - | 13/51 (25.4) |
| EW (n = 228) | 12 (5.2) | nt$ | 10 (4.4) | 5 (2.1) | 14 (6.1) | 6 (2.6) | 5 (2.1) | 8 (3.5) | 4 (2.9)* | 3 (1.72)* | 10 (5.7)* | 44/228(19.2) |
| EB (n = 236) | 11 (4.66) | nt | 7 (3.0) | 3 (1.2) | 5 (2.1) | 3 (1.2) | 4 (1.7) | 4 (4.5) | 2 (1.6)* | 1 (0.6)* | 3 (1.8)* | 25/236(10.5) |
| MS (n = 94) | 3 (3.2) | 6 (6.4%) | 7 (7.4) | 4 (4.2) | 6 (6.4) | 4 (4.2) | 4 (4.2) | 4 (4.5) | 6 (6.4) | 5 (5.4) | 1 (1.0) | 17/94 (18.0) |
| MN (n = 506) | 12 (2.3) | 12 (7.6%)# | 17 (3.3) | 12 (2.3) | 17 (3.3) | 10 (1.9) | 12 (2.3) | 14 (2.8) | 9 (2.7)* | 1 (0.3)* | 9 (2.7)* | 68/506(13.4) |
| Total | 40 (2.72) | 26 (3.95) | 47 (3.19) | 32 (2.17) | 50 (3.40) | 28 (1.90) | 37 (2.51) | 40 (2.72) | 26 (2.23) | 17 (1.46) | 29 (2.49) | |
| DRC (n = 630) | ||||||||||||
| MBk(n = 125) | 2 (1.6) | 6 (4.8%) | 3 (2.4) | - | 2 (1.6) | 1 (0.8) | - | - | 5 (4.0) | 8 (6.4) | 6 (4.8) | 20/125 (16.0) |
| ML (n = 45) | - | 12 (2.7%) | 5 (11) | 2 (4.4) | 1 (2.2) | 2 (4.4) | 1 (2.2) | 2 (4.4) | 3 (6.6) | 4 (8.8) | 10 (22) | 21/45 (46.6) |
| MK (n = 29) | - | 1 (3.4%) | 1 (3.4) | 1 (3.4) | 2 (6.8) | 1 (3.4) | 4 (13) | 1 (3.4) | 2 (6.8) | 2 (6.8) | 2 (6.8) | 8/29 (27.5) |
| KL (n = 280) | 5 (1.8) | 11 (4.3%)# | 7 (2.5) | 7 (2.5) | 5 (1.8) | 6 (2.1) | 8 (2.8) | 6 (2.1) | 8 (3.1)* | 6 (2.3)* | 7 (2.7)* | 32/280 (11.4) |
| WK (n = 39) | 14 (35) | nt | 2 (5.1) | 1 (2.5) | - | 1 (2.5) | - | - | nt | nt | nt | 15/39 (38.4) |
| GM (n = 112) | 6 (5.3) | nt | - | - | - | 1 (0.9) | - | - | nt | nt | nt | 7/112 (6.2) |
| Total | 27 (4.28) | 30 (6.63) | 18 (2.85) | 11 (1.74) | 10 (1.58) | 12 (1.89) | 13 (2.06) | 9 (1.42) | 18 (3.96) | 20 (4.42) | 25 (5.53) | |
a Total number of samples reactive with one or more antigens.
b -: no positive samples were identified.
c number of positives (percentages).
* Total numbers tested are different: Cameroon: n = 1161(EW = 174; EB = 158; MN = 329); DRC. n = 452 (KL = 253).
# Total numbers tested are different: Cameroon: n = 657 (MN = 157); DRC: n = 452 (KL = 253).
$: nt = not tested.